{
  "slug": "counterfeit-medicine-death",
  "question": "What are the odds of being harmed or killed by a counterfeit or substandard medicine?",
  "category": "health",
  "no_reliable_estimate": false,
  "perceived": {
    "description": "In high-income countries with stringent pharmaceutical regulation, the idea of receiving a fake or substandard medicine feels like a plot device from a thriller rather than a routine hazard. Pharmacies are licensed, supply chains are audited, and regulatory agencies pull defective batches within days. The mental model of a medicine simply not containing the drug on its label does not map onto everyday experience. In low- and middle-income countries the situation is categorically different: WHO estimates that 1 in 10 medical products in these settings is substandard or falsified, and the consequences are not merely inefficacy but death, particularly among children treated with fake antibiotics for pneumonia or counterfeit antimalarials for malaria.\n",
    "kind": "intuition"
  },
  "native": {
    "display": "~188,000 deaths per year globally from substandard or falsified medicines",
    "numerator": 188000,
    "denominator": 5000000000,
    "unit": "per year",
    "population": "global adults and children"
  },
  "normalized": {
    "lifetime_us_adult": 0.00277,
    "display": "~1 in 361 lifetime (LMIC adult)",
    "log_value": -2.56,
    "assumptions": "Native rate: WHO-commissioned models estimate 72,000-169,000 child deaths per year from pneumonia caused by substandard/falsified antibiotics (University of Edinburgh model) and 116,000 (64,000-158,000) additional deaths from malaria caused by substandard/falsified antimalarials in sub-Saharan Africa (London School of Hygiene and Tropical Medicine model). A conservative combined estimate of ~188,000 deaths/yr is used, reflecting overlap between model ranges. The burden falls almost entirely on low- and middle-income countries (LMICs), where ~4 billion people live and where WHO estimates 1 in 10 medical products is substandard or falsified. Dividing by the at-risk population: 188,000 / 4,000,000,000 = 4.7e-5 annual rate. Lifetime conversion using the 59-year horizon: 1 - (1 - 4.7e-5)^59 = 0.00277. Uncertainty low bound uses 100,000 deaths (conservative floor accounting for model uncertainty and possible double-counting between the Edinburgh and LSHTM models) / 4B compounded 59 years = 1 - (1 - 2.5e-5)^59 = 0.0015. High bound uses 370,000 (169,000 + 158,000 plus ~15% for non-pneumonia/non-malaria categories) / 4B compounded 59 years = 1 - (1 - 9.25e-5)^59 = 0.0055. The true death toll is likely higher since these models cover only pneumonia and malaria, not cardiovascular, HIV/AIDS, or TB medicines. For adults in high-income countries with robust drug-quality regulation, personal risk is orders of magnitude lower.\n",
    "uncertainty": {
      "low": 0.0015,
      "high": 0.0055
    },
    "scope": "subgroup_lifetime"
  },
  "sources": [
    {
      "url": "https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products",
      "title": "Substandard and falsified medical products — Fact sheet",
      "publisher": "World Health Organization",
      "source_type": "govt_report",
      "statistic": "At least 1 in 10 medicines in low- and middle-income countries are substandard or falsified; countries spend an estimated US$ 30.5 billion per year on such products",
      "excerpt": "\"At least 1 in 10 medicines in low- and middle-income countries are substandard or falsified. Countries spend an estimated US$ 30.5 billion per year on substandard and falsified medical products.\"\n",
      "source_date": "2018-01-31",
      "source_accessed": "2026-04-26",
      "archive_url": "http://web.archive.org/web/20260415174758/https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products",
      "calculation_notes": "The WHO fact sheet has been restructured since the original access date. The detailed mortality models (University of Edinburgh pneumonia estimate of 72,000-169,000 deaths and LSHTM malaria estimate of 116,000 deaths) that previously anchored the native numerator are no longer present on this page. The 1-in-10 prevalence figure remains and establishes the scale of the problem in LMICs. The mortality estimates that underpin the 188,000 deaths/year figure were derived from earlier versions of this fact sheet and from the original research publications (Lancet Infectious Diseases, 2018). 188,000 / 5B = 0.0000376 annual rate, compounded over 59 years yields 0.00222.\n",
      "independence_note": "Both sources are WHO publications drawing on the same underlying data and commissioned modelling studies. They are not independent data sources.\n"
    },
    {
      "url": "https://www.who.int/health-topics/substandard-and-falsified-medical-products",
      "title": "Substandard and falsified medical products — Health topics",
      "publisher": "World Health Organization",
      "source_type": "govt_report",
      "statistic": "More than 1 in 10 medicines in LMICs estimated substandard or falsified; up to 2 billion people lack access to necessary medicines",
      "excerpt": "\"Up to two billion people around the world lack access to necessary medicines, vaccines, medical devices including in vitro diagnostics, and other health products, which creates a vacuum that is too often filled by substandard and falsified products. More than one in ten medicines in low- and middle-income countries are estimated to be substandard or falsified. No country remains untouched from this issue.\"\n",
      "source_date": "2020-06-01",
      "source_accessed": "2026-04-26",
      "archive_url": "http://web.archive.org/web/20260310165041/https://www.who.int/health-topics/substandard-and-falsified-medical-products",
      "calculation_notes": "This WHO health-topics page confirms the 1-in-10 prevalence framing and establishes the access-gap context (2 billion people lacking necessary medicines). The previously cited sub-URL with \"hundreds of thousands\" mortality framing is no longer accessible; the current page focuses on prevalence, impact, and WHO response. The mortality estimates underpinning the 188,000 figure are supported by the original Lancet Infectious Diseases publications rather than this summary page.\n",
      "independence_note": "Same WHO data as source 1; different summary page, not an independent data source.\n"
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4455082/",
      "title": "Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa",
      "publisher": "The American Journal of Tropical Medicine and Hygiene — Renschler JP, Walters KM, Newton PN, Laxminarayan R",
      "source_type": "peer_reviewed",
      "statistic": "Approximately 122,350 (IQR: 91,577–154,736) under-five deaths in 39 sub-Saharan African countries in 2013 were associated with consumption of poor-quality antimalarials, representing ~3.75% of all under-five deaths in those countries",
      "excerpt": "\"An estimated 122,350 (interquartile range [IQR]: 91,577–154,736) under-five malaria deaths were associated with consumption of poor-quality antimalarials across 39 sub-Saharan African countries in 2013. This represented 3.75% of all under-five deaths in our sample of countries.\"\n",
      "source_date": "2015-06-01",
      "source_accessed": "2026-05-03",
      "archive_url": "http://web.archive.org/web/20250924001100/https://pmc.ncbi.nlm.nih.gov/articles/PMC4455082/",
      "calculation_notes": "Renschler et al. (2015) is the peer-reviewed modeling paper that independently quantifies child deaths from poor-quality antimalarials, using WHO child mortality data and antimalarial failure rate estimates for 39 sub-Saharan African countries. The 122,350 central estimate (IQR 91,577–154,736) is consistent with the LSHTM model figure of 116,000 (64,000–158,000) cited in WHO documentation; slight differences reflect model assumptions and reference year (2013 here vs. the WHO model's reference year). The overlapping uncertainty intervals confirm the same order-of-magnitude burden. This study covers malaria deaths only; combined with the Edinburgh University pneumonia model (72,000–169,000 deaths), the composite ~188,000 estimate is conservative. Used here as the independent peer-reviewed anchor confirming the malaria component of the native rate.\n",
      "independence_note": "Independent of the WHO sources above: this is an academic modelling study published in a peer-reviewed journal (Am J Trop Med Hyg), authored by researchers at Princeton and Oxford (Paul N Newton of MORU/Oxford; Ramanan Laxminarayan of Princeton), using WHO child mortality inputs but applying an independent methodological framework to estimate attributable deaths.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Death from rabies via dog bite (lifetime, global adult)",
      "lifetime_us_adult": 0.00069
    },
    {
      "label": "Death from food poisoning (lifetime, US)",
      "lifetime_us_adult": 0.000019
    },
    {
      "label": "Death from household air pollution (lifetime, global adult)",
      "lifetime_us_adult": 0.0337
    }
  ],
  "regional_breakdown": [
    {
      "region": "LMIC adults (~4 billion)",
      "probability": 0.00277,
      "notes": "WHO estimates 1 in 10 medical products in LMICs is substandard or falsified"
    },
    {
      "region": "Global average (all adults)",
      "probability": 0.00222,
      "notes": "Diluted across 5B adults; misleading because risk concentrates in LMICs"
    },
    {
      "region": "High-income countries (regulated pharmacies)",
      "probability": 0.00001,
      "notes": "Effectively negligible; robust pharmaceutical regulation and supply-chain integrity"
    }
  ],
  "short_label": "Counterfeit medicine",
  "myth_framing": "underrated",
  "outcome_severity": "fatal",
  "exposure_pattern": "recurring",
  "outcome_type": "death",
  "valence": "negative",
  "caveats": "The 188,000 deaths estimate is derived from two disease-specific models covering only pneumonia and malaria. The true global death toll from substandard and falsified medicines is almost certainly higher when cardiovascular drugs, HIV/AIDS antiretrovirals, tuberculosis medicines, and other therapeutic categories are included. The burden falls almost entirely on low- and middle-income countries with weak pharmaceutical regulatory systems. For any adult purchasing medicines through a regulated pharmacy in the US, EU, Japan, or other high-income country with robust drug-quality enforcement, the personal probability of encountering a substandard or falsified medicine is orders of magnitude lower than the global average. Online pharmacies operating outside regulatory oversight present a distinct and growing risk channel even in wealthy countries.\n",
  "quality_score": {
    "d1": 4,
    "d2": 3,
    "d3": 4,
    "d4": 4,
    "d5": 4,
    "d6": 4,
    "d7": 3,
    "d8": 4,
    "avg": 3.75,
    "scored_by": "extracted-from-transcript",
    "scored_at": "2026-05-03",
    "methodology_version": "1.0"
  },
  "reviewer": "8d-eval-2026-05-16",
  "last_reviewed": "2026-05-16",
  "reviewed": true,
  "generated_at": "2026-04-24",
  "image": {
    "alt": "A flat vector illustration of a medicine capsule with a subtle question mark shadow, rendered in muted tones against a pale background."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/counterfeit-medicine-death"
}